ArrowMark Colorado Holdings
ALNY icon

ArrowMark Colorado Holdings’s Alnylam Pharmaceuticals ALNY Stock Holding History

ArrowMark Colorado Holdings’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,534
Closed -$223K – 334
2020
Q3 		$223K Hold
1,534
– – ﹤0.01% 325
2020
Q2 		$227K Sell
1,534
-1,967
-56% -$265K ﹤0.01% 291
2020
Q1 		$381K Sell
3,501
-1,076
-24% -$124K 0.01% 281
2019
Q4 		$527K Hold
4,577
– – ﹤0.01% 289
2019
Q3 		$368K Sell
4,577
-12,475
-73% -$987K ﹤0.01% 297
2019
Q2 		$1.24M Buy
17,052
+29
+0.2% +$2.23K 0.01% 266
2019
Q1 		$1.59M Sell
17,023
-17,921
-51% -$1.5M 0.02% 255
2018
Q4 		$2.55M Hold
34,944
– – 0.03% 254
2018
Q3 		$3.06M Hold
34,944
– – 0.03% 262
2018
Q2 		$3.44M Sell
34,944
-1,223
-3% -$121K 0.03% 252
2018
Q1 		$4.31M Sell
36,167
-272,872
-88% -$35.2M 0.04% 225
2017
Q4 		$39.3M Sell
309,039
-194,850
-39% -$24.5M 0.4% 85
2017
Q3 		$59.2M Sell
503,889
-34,400
-6% -$2.94M 0.67% 50
2017
Q2 		$42.9M Sell
538,289
-67,854
-11% -$4.34M 0.53% 69
2017
Q1 		$31.1M Sell
606,143
-86,593
-13% -$4M 0.42% 84
2016
Q4 		$25.9M Buy
692,736
+301,877
+77% +$12.6M 0.41% 82
2016
Q3 		$26.5M Buy
390,859
+19,309
+5% +$1.36M 0.48% 73
2016
Q2 		$20.6M Buy
371,550
+60,977
+20% +$3.84M 0.42% 84
2016
Q1 		$19.5M Buy
310,573
+133,891
+76% +$8.9M 0.43% 81
2015
Q4 		$16.6M Buy
176,682
+159,081
+904% +$14.7M 0.45% 74
2015
Q3 		$1.41M Buy
17,601
+6,286
+56% +$698K 0.04% 211
2015
Q2 		$1.36M Hold
11,315
– – 0.03% 223
2015
Q1 		$1.18M Sell
11,315
-159,092
-93% -$16.1M 0.03% 221
2014
Q4 		$16.5M Sell
170,407
-51,533
-23% -$4.77M 0.42% 72
2014
Q3 		$17.3M Sell
221,940
-38,374
-15% -$2.48M 0.48% 69
2014
Q2 		$16.4M Buy
260,314
+129,747
+99% +$7.71M 0.47% 79
2014
Q1 		$8.77M Sell
130,567
-1,412
-1% -$109K 0.28% 123
2013
Q4 		$8.49M Buy
131,979
+96,979
+277% +$5.79M 0.26% 128
2013
Q3 		$2.24M Sell
35,000
-8,400
-19% -$419K 0.07% 177
2013
Q2 		$1.34M Buy
+43,400
New +$1.15M 0.36% 60

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

ArrowMark Colorado Holdings's ALNY Position: Q4 2020 in Review

ArrowMark Colorado Holdings sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2020, closing a stake of 1,534 shares — an estimated $223K sold.

ArrowMark Colorado Holdings first reported a position in ALNY in Q2 2013 and held it in 30 quarters. The position peaked at $59.2M in Q3 2017. 376 funds tracked by Wall St. Rank hold ALNY as of Q4 2020.

  • ArrowMark Colorado Holdings reported no remaining Alnylam Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • ArrowMark Colorado Holdings sold 1,534 Alnylam Pharmaceuticals shares in Q4 2020, an estimated $223K.
  • ArrowMark Colorado Holdings first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 30 quarters.
  • ArrowMark Colorado Holdings's Alnylam Pharmaceuticals position peaked at $59.2M in Q3 2017.
  • 376 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2020.

Based on ArrowMark Colorado Holdings's 13F filing for Q4 2020, filed 16 Feb 2021.